Kalshi is launching a new prediction market that lets users place bets on outcomes related to experimental drugs, including results from clinical trials and subsequent FDA decisions. The market is designed to allow wagers on how specific developments in the drug development process will turn out, effectively translating forecasted events into contract pricing.
According to reporting, the new offering expands Kalshi’s range beyond conventional categories to include events that are tied to regulatory and clinical milestones. In addition to clinical trial performance, the market also includes wagers tied to whether the FDA approves an experimental drug.
The announcement is framed as an extension of Kalshi’s trading model—contracts that reflect probabilities of future events—applied to the pharmaceutical research and approval pipeline. The sources also describe it as enabling betting on drug outcomes that depend on both trial results and regulatory action, which could attract interest from participants seeking to speculate on the timing and nature of FDA determinations.
